Charles River Laboratories Intl. Inc vs Gigacloud Technology Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Gigacloud Technology Inc trades at $35.78 (market cap $1.32B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 8.4× Gigacloud Technology Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Gigacloud Technology Inc nearer its low. Which is the better fit depends on your goals.
| CRL | GCT | |
|---|---|---|
Market Cap | $11.14B | $1.32B |
Sector | Health | Technology |
52-Week High | $233.60 | $51.80 |
52-Week Low | $145.57 | $20.26 |
Enterprise Value | $14.00B | $1.43B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GigaCloud Technology (GCT) trades at $35.40, up 2.88% today, showing strong momentum with consistent earnings beats and robust fundamentals. The stock exhibits a bullish technical signal with key resistance at $36 and support at $34. Recent financials reveal impressive profitability with a 10.77% net income margin and 32.14% ROE, while valuation ratios like P/E of 8.96 suggest potential undervaluation. Positive media coverage highlights growth prospects, including recognition as a 'World Growth Leader' by TIME in June 2026.
Outlook remains positive due to earnings growth and operational efficiency, but risks include market volatility and competitive pressures. Analyst consensus is bullish with 67% buy ratings, supporting upside potential if execution continues. Investors should weigh strong cash flow against sector-specific headwinds for balanced decision-making.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →